Stocks · News reference
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.20) by 45 percent. This is a 63.33 percent increase over losses of $(0.30) per share
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Relmada Therapeutics (NASDAQ:RLMD) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time
I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The slides look terrific. The market opportunity is enormous.
Filed: 2026-09-08 AccNo: 0001213900-26-097851 Size: 187 KB Item 8.01: Other Events